FI3778573T3 - Yhdiste, jolla on syöpää ehkäisevä vaikutus - Google Patents
Yhdiste, jolla on syöpää ehkäisevä vaikutus Download PDFInfo
- Publication number
- FI3778573T3 FI3778573T3 FIEP19774768.6T FI19774768T FI3778573T3 FI 3778573 T3 FI3778573 T3 FI 3778573T3 FI 19774768 T FI19774768 T FI 19774768T FI 3778573 T3 FI3778573 T3 FI 3778573T3
- Authority
- FI
- Finland
- Prior art keywords
- formula
- group represented
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 21
- 230000001093 anti-cancer Effects 0.000 title 1
- -1 tetrahydro-1H-azepinyl Chemical group 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 101710148027 Ribulose bisphosphate carboxylase/oxygenase activase 1, chloroplastic Proteins 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018068816 | 2018-03-30 | ||
| PCT/JP2019/014042 WO2019189778A1 (ja) | 2018-03-30 | 2019-03-29 | 抗がん活性を有する化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3778573T3 true FI3778573T3 (fi) | 2024-06-27 |
Family
ID=68062014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19774768.6T FI3778573T3 (fi) | 2018-03-30 | 2019-03-29 | Yhdiste, jolla on syöpää ehkäisevä vaikutus |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11629152B2 (https=) |
| EP (1) | EP3778573B1 (https=) |
| JP (2) | JP7374887B2 (https=) |
| KR (1) | KR102765467B1 (https=) |
| CN (1) | CN111936468B (https=) |
| AU (1) | AU2019242518B2 (https=) |
| BR (1) | BR112020019963A2 (https=) |
| CA (1) | CA3095415A1 (https=) |
| DK (1) | DK3778573T3 (https=) |
| ES (1) | ES2980254T3 (https=) |
| FI (1) | FI3778573T3 (https=) |
| HR (1) | HRP20240788T1 (https=) |
| HU (1) | HUE066972T2 (https=) |
| MX (1) | MX2020009967A (https=) |
| PL (1) | PL3778573T3 (https=) |
| PT (1) | PT3778573T (https=) |
| RS (1) | RS65692B1 (https=) |
| SG (1) | SG11202009088VA (https=) |
| SI (1) | SI3778573T1 (https=) |
| TW (1) | TWI825085B (https=) |
| WO (1) | WO2019189778A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629152B2 (en) * | 2018-03-30 | 2023-04-18 | Kyowa Kirin Co., Ltd. | Compound with anticancer activity |
| CN120623106A (zh) * | 2019-09-30 | 2025-09-12 | 协和麒麟株式会社 | Bet降解剂 |
| CN110693864B (zh) * | 2019-10-31 | 2022-08-26 | 重庆医科大学 | 一类三羰基化合物在制备抗人宫颈癌药物中的应用 |
| JP7419406B2 (ja) * | 2020-02-06 | 2024-01-22 | 田辺三菱製薬株式会社 | Ｂｒｄ４蛋白質分解誘導作用を有するスルホンアミドあるいはスルフィンアミド化合物及びその医薬としての用途 |
| JP7614145B2 (ja) * | 2021-08-05 | 2025-01-15 | 田辺三菱製薬株式会社 | Ｂｒｄ４蛋白質分解誘導剤を含む医薬 |
| WO2025127150A1 (ja) * | 2023-12-15 | 2025-06-19 | 協和キリン株式会社 | ２価ｂｅｔ分解薬およびターゲティング分子－薬物複合体 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3849458A (en) | 1966-01-21 | 1974-11-19 | Incentive Res & Dev Ab | Method for deuterating organic compounds |
| JPS61148141A (ja) | 1984-12-21 | 1986-07-05 | Mitsubishi Rayon Co Ltd | 重水素化アクリル酸メチルまたは重水素化メタクリル酸メチルの製造法 |
| JPS61275241A (ja) | 1985-05-29 | 1986-12-05 | Mitsubishi Rayon Co Ltd | 重水素化アクリル酸又は重水素化メタクリル酸の製造方法 |
| JPS61277648A (ja) | 1985-06-03 | 1986-12-08 | Mitsubishi Rayon Co Ltd | 重水素化アクリル酸又は重水素化メタクリル酸の製造方法 |
| DE3701302A1 (de) | 1987-01-17 | 1988-07-28 | Hoechst Ag | Verfahren zur herstellung von deuterierten organischen verbindungen |
| GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201107325D0 (en) * | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| HUE043568T2 (hu) | 2013-03-14 | 2019-08-28 | Glaxosmithkline Ip No 2 Ltd | 2,3-diszubsztituált 1-acil-4-amino-1,2,3,4-tetrahidrokinolin származékok és bromodomén inhibitorokkénti felhasználásuk |
| WO2015081284A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| CA2966450A1 (en) | 2014-12-17 | 2016-06-23 | Olesya KHARENKO | Inhibitors of bromodomains |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| MX2018006499A (es) * | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos. |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| WO2018111805A1 (en) | 2016-12-13 | 2018-06-21 | St. Jude Children's Research Hospital | Tetrahydroquinoline-based bromodomain inhibitors |
| US11629152B2 (en) * | 2018-03-30 | 2023-04-18 | Kyowa Kirin Co., Ltd. | Compound with anticancer activity |
-
2019
- 2019-03-29 US US17/043,348 patent/US11629152B2/en active Active
- 2019-03-29 ES ES19774768T patent/ES2980254T3/es active Active
- 2019-03-29 TW TW108111333A patent/TWI825085B/zh active
- 2019-03-29 FI FIEP19774768.6T patent/FI3778573T3/fi active
- 2019-03-29 HR HRP20240788TT patent/HRP20240788T1/hr unknown
- 2019-03-29 RS RS20240753A patent/RS65692B1/sr unknown
- 2019-03-29 CA CA3095415A patent/CA3095415A1/en active Pending
- 2019-03-29 CN CN201980023780.2A patent/CN111936468B/zh active Active
- 2019-03-29 EP EP19774768.6A patent/EP3778573B1/en active Active
- 2019-03-29 BR BR112020019963-0A patent/BR112020019963A2/pt unknown
- 2019-03-29 PT PT197747686T patent/PT3778573T/pt unknown
- 2019-03-29 KR KR1020207030929A patent/KR102765467B1/ko active Active
- 2019-03-29 MX MX2020009967A patent/MX2020009967A/es unknown
- 2019-03-29 SG SG11202009088VA patent/SG11202009088VA/en unknown
- 2019-03-29 PL PL19774768.6T patent/PL3778573T3/pl unknown
- 2019-03-29 HU HUE19774768A patent/HUE066972T2/hu unknown
- 2019-03-29 DK DK19774768.6T patent/DK3778573T3/da active
- 2019-03-29 SI SI201930782T patent/SI3778573T1/sl unknown
- 2019-03-29 AU AU2019242518A patent/AU2019242518B2/en active Active
- 2019-03-29 WO PCT/JP2019/014042 patent/WO2019189778A1/ja not_active Ceased
- 2019-03-29 JP JP2020511101A patent/JP7374887B2/ja active Active
-
2023
- 2023-01-25 US US18/101,362 patent/US12054494B2/en active Active
- 2023-10-24 JP JP2023182872A patent/JP7631473B2/ja active Active
-
2024
- 2024-06-21 US US18/751,106 patent/US20240360149A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3778573T3 (fi) | Yhdiste, jolla on syöpää ehkäisevä vaikutus | |
| Ghorab et al. | Synthesis of novel pyrrole and pyrrolo [2, 3-d] pyrimidine derivatives bearing sulfonamide moiety for evaluation as anticancer and radiosensitizing agents | |
| CY1121501T1 (el) | Συνδυαστικη θεραπεια με ενα μιτωτικο αναστολεα | |
| Marzo et al. | Antimitotic drugs in cancer chemotherapy: promises and pitfalls | |
| Richardson et al. | Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers | |
| EP3525886B1 (en) | Compositions comprising a metal source, dithiocarbamate and cyclodextrin | |
| UY28736A1 (es) | Derivados de quinazolina | |
| UY29562A1 (es) | Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| UY29093A1 (es) | Derivados de 4-oxo-3. 4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones que los contienen, procesos de preparación y aplicaiones. | |
| CL2012000489A1 (es) | Compuestos dimeros de pirrolo[2,1 c][1,4]benzodiazepin-5-ona (tomaimicina); conjugados de estos compuestos; procedimiento de preparacion de los conjugados; composicion farmaceutica que comprende a los compuestos o al conjugado; y uso de los compuestos y del conjugado como anticancerosos. | |
| CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
| UY28522A1 (es) | Derivados de quinazolina | |
| UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| Sheta et al. | Novel imidazolone derivatives as potential dual inhibitors of checkpoint kinases 1 and 2: Design, synthesis, cytotoxicity evaluation, and mechanistic insights | |
| AU2012249262A1 (en) | Azolium and purinium salt anticancer and antimicrobial agents | |
| Aruchamy et al. | Design, synthesis, and anti-breast cancer potential of imidazole–pyridine hybrid molecules in vitro and ehrlich ascites carcinoma growth inhibitory activity assessment in vivo | |
| Kumar et al. | Recent advances in chalcone-based anticancer heterocycles: A structural and molecular target perspective | |
| Ahmad | Therapeutic significance of molecular hybrids for breast cancer research and treatment | |
| JP2020534274A5 (https=) | ||
| Fong | The extravascular penetration of tirapazamine into tumours: a predictive model of the transport and efficacy of hypoxia specific cytotoxic analogues and the potential use of cucurbiturils to facilitate delivery | |
| JP2019519524A5 (https=) | ||
| Laxmikeshav et al. | Exploration of benzimidazoles as potential microtubule modulators: An insight in the synthetic and therapeutic evolution | |
| UY28108A1 (es) | Nuevos derivados de arilen- (2-amino-fenil)-carboxamida, su elaboracion y su uso como agentes farmaceuticos | |
| CO2024014595A2 (es) | Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina | |
| EA201390716A1 (ru) | Комбинированная терапия внеклеточным доменом fgfr1 |